PRESS RELEASE AND MEDIA

Kerry Logistics Network Limited (‘KLN’; Stock Code 0636.HK), through its subsidiary, Kerry Pharma, and Teva Pharmaceutical Hong Kong Limited (‘Teva’) entered into an exclusive agreement for fourth-party logistics (4PL) distribution services in Hong Kong, Macau and other markets in the Greater Bay Area. As the sole distributor of the complete range of Teva’s products, Kerry Pharma manages Teva’s supply chains with end-to-end pharmaceutical logistics solutions, ensuring seamless distribution and stable product availability at all times.

The collaboration serves to strengthen KLN’s position and deepen its foothold in the pharmaceutical logistics sector, which is essential to public health, while enabling Teva to focus on its core business with strengthened logistics support, enhanced operational efficiency and swift market responsiveness.

KLN’s dedicated 4PL fulfilment solutions cover inbound logistics, warehousing, distribution, billing, reporting and exports, managing a portfolio of 190 SKUs and over 3,000 delivery points, from hospital pharmacies, clinics to drug stores and key chain channels. Leveraging its multi-temperature storage capability, KLN maintains strict temperature controls for Teva’s general pharmaceuticals and sensitive items, including dangerous drugs, ensuring complete cold chain integrity for all products. For deliveries within the Greater Bay Area, KLN offers ocean freight and air freight, respectively, supported by KLN’s cold chain solutions.

Samuel Lau, Managing Director - Integrated Logistics Asia of KLN, said, “This exclusive partnership not only underscores KLN’s commitment to delivering high-quality services, but also enhances our ability to manage Teva's extensive product range effectively. As the sole distributor of Teva’s product range, we also handle the crucial regulatory requirements such as import licenses and liaison with the Department of Health, ensuring hassle-free customer experience for Teva. This exclusivity also enables us to foster a deeper collaboration with Teva, aligning our goals and resources to better serve our customers and respond swiftly to market demands.”

Theodor Wee, General Manager of Teva Greater China, said, “The stable supply of medicines is crucial to patient health, and Teva is always committed to exploring innovative initiatives to improve patient access to medicines continuously. This collaboration also exemplifies Teva’s global ‘Pivot to Growth’ strategy. In the future, we will accelerate to bring more medicines that will meet the evolving needs of patients. Teva looks forward to partnering with Kerry Pharma to promote medical integration and innovation in the Greater Bay Area, leveraging each other's strengths as a model of cooperation.”